BioSpace News Archive

Genetown

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, outlined business updates and strategic priorities for 2024.

January 8, 2024
·
10 min read
Business

Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, provided a business update including preliminary estimates of fourth quarter and full year net revenue and cash, cash equivalents and marketable securities.

January 8, 2024
·
10 min read
Drug Development

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

Cartesian Therapeutics, Inc. announced positive twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis, a chronic autoimmune disorder that causes disabling muscle weakness and fatigue.

January 8, 2024
·
7 min read
Drug Development

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease

OKYO Pharma Limited reports positive safety and efficacy results in its Phase 2, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of OK-101 ophthalmic solution in subjects with DED.

January 8, 2024
·
9 min read
Biotech Beach

Travere Therapeutics Provides Corporate Update and 2024 Outlook

Travere Therapeutics, Inc. announced that, based on preliminary and unaudited financial data, the Company expects net product sales from continuing operations for the fourth quarter of 2023 to be approximately $40 million.

January 8, 2024
·
15 min read
Bio NC

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

Shattuck Labs, Inc. provided a corporate update and highlighted upcoming key milestones anticipated in 2024.

January 8, 2024
·
7 min read
Deals

Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Axonics, Inc., a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.

January 8, 2024
·
8 min read
Biotech Bay

Taiho Ventures Expands Investment Pool to $400 Million to Continue Quality Investments and Accelerate Open Innovation

Taiho Pharmaceutical Co., Ltd. and Taiho Ventures, LLC, a strategic corporate venture capital arm of Taiho Pharmaceutical, announced that Taiho Ventures has increased its investment pool by $100 million from $300 million to $400 million.

January 8, 2024
·
2 min read
NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)

NorthStar Medical Radioisotopes, LLC and Alpha-9 Oncology Inc. announced a long-term strategic supply agreement for NorthStar to provide Alpha-9 with its non-carrier added Ac-225 for use in its development and clinical programs.

January 8, 2024
·
5 min read
Deals

Axonics Announces Definitive Agreement to be Acquired by Boston Scientific

Axonics, Inc. announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation for $71 in cash per share, representing an equity value of approximately $3.7 billion.

January 8, 2024
·
7 min read